Dense ECM in the TME is majorly constituted of hyaluronic acid and collagen and, therefore, approaches over the last two decades have focused on ECM targeting by the administration of pegylated hyaluronidase, reduction in collagen crosslinking by Lysyl oxidase (LOX) targeting or collagen synthesis through TGFβ inhibition, and decreasing fibrosis by vitamin D receptor ligand in different tumor xenografts 100. This evidence concerns the gene LOX and neoplasm.